ArticleEvolution, medicine, and public health2020
Phage steering of antibiotic-resistance evolution in the bacterial pathogen,
Article in Evolution, medicine, and public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 92 citations in OpenAlex.
- Calciphylaxis complicated by NDM-1-producing Pseudomonas aeruginosa: first experience with cefepime-zidebactam alongside phage therapy in the USA.The Lancet. Infectious diseases · 2026Review
- A consensus-based guideline for personalized bacteriophage therapy.Nature medicine · 2026Review
- WaaL-WaaP receptor cross-talk drives phage-induced collateral sensitivity to colistin in Salmonella Pullorum.Veterinary research · 2026Article
- Mechanisms of Resistance, Insights From Case Reports, and Future Prospects in Mycobacteriophage Therapy.Journal of the Royal Society of New Zealand · 2026Review
- Short-Term Bacteriophage Exposure Is Associated with Shifts in Antibiotic Susceptibility Profiles of ClinicalMicroorganisms · 2026Article
- Giving Antibiotics a Second Chance: Evolutionary Trade-Offs and Phage-Driven Restoration of Antibiotic Susceptibility.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Comparison and correlation of in vitro and in vivo approaches for determining Pseudomonas aeruginosa bacteriophages activity.BMC microbiology · 2026Article
- Genomic and in vitro characterization of two lytic bacteriophages infecting multidrug-resistant Erwinia sp. strain AnSW2-5.Scientific reports · 2026Article
- Steering the course: targeting and exploiting surface receptors in phage therapy.Journal of bacteriology · 2026Review
- Engineering T3 and T7 host range to target protein receptors and guide bacterial evolution.iScience · 2026Article
- Characterization and phage-antibiotic synergy of bacteriophages PES-1 and PES-2 against porcine enterotoxigenicFrontiers in microbiology · 2026Article
- Targeted isolation of TolC-dependent phages reveals dual strategies for combating multidrug-resistant avianFrontiers in microbiology · 2026Article
- Molecular Framework of Multidrug Resistance in Pseudomonas aeruginosa.Current microbiology · 2025Review
- Biologic drug development for treatment and prevention of sexually transmitted infections.Clinical microbiology reviews · 2025Review
- Review
- Biocontrol of Phage Resistance inViruses · 2025Review
- Phage Therapy for Urinary Tract Infections: Progress and Challenges Ahead.International urogynecology journal · 2025Review
- Phage steering in the presence of a competing bacterial pathogen.Microbiology spectrum · 2025Article
- The Current Landscape of Phage-Antibiotic Synergistic (PAS) Interactions.Antibiotics (Basel, Switzerland) · 2025Review
- A flagella-dependentmBio · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
BACKGROUND AND
objectivesAntimicrobial resistance is a growing global concern and has spurred increasing efforts to find alternative therapeutics. Bacteriophage therapy has seen near constant use in Eastern Europe since its discovery over a century ago. One promising approach is to use phages that not only reduce bacterial pathogen loads but also select for phage resistance mechanisms that trade-off with antibiotic resistance-so called 'phage steering'. METHODOLOGY: Recent work has shown that the phage OMKO1 can interact with efflux pumps and in so doing select for both phage resistance and antibiotic sensitivity of the pathogenic bacterium
resultsWe show that CONCLUSIONS AND IMPLICATIONS: Our study supports a trade-off between antibiotic resistance and phage sensitivity. This trade-off was maintained over co-evolutionary time scales even under combined phage and antibiotic pressure. Similarly, OMKO1 maintained this trade-off
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.